Small cell lung cancer: Clinical practice guidelines in oncology

Gregory P. Kalemkerian*, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O'MalleyJyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams, Kristina Gregory, Miranda Hughes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

201 Scopus citations

Abstract

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

Original languageEnglish (US)
Pages (from-to)78-98
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Small cell lung cancer: Clinical practice guidelines in oncology'. Together they form a unique fingerprint.

Cite this